Kelly M Bailey1,2, Alison B Durham3, Lili Zhao4, Doug Fullen5, James Geiger6, Carol Bradford7, Valerie Opipari1, Timothy Johnson3, Rajen Mody1. 1. Department of Pediatrics, The University of Michigan, Ann Arbor, MI, USA. 2. Department of Pediatrics, The University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Dermatology, The University of Michigan, Ann Arbor, MI, USA. 4. Department of Biostatistics, The University of Michigan, Ann Arbor, MI, USA. 5. Department of Pathology, The University of Michigan, Ann Arbor, MI, USA. 6. Department of Pediatric Surgery, The University of Michigan, Ann Arbor, MI, USA. 7. Department of Otolaryngology, The University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: The diagnosis and management of pediatric melanomas is challenging given the presence of both melanomas and histologically aggressive Spitz tumors of undetermined biological significance (S-UBS) in this age group. Study objectives were to examine: factors leading to diagnostic delays, therapy side effects and patient outcomes in these diagnostic groups. METHODS: A retrospective case review was performed using The University of Michigan's pediatric oncology database over a 13-year timespan. Patients referred to our clinic for consideration of interferon therapy due to a diagnosis of a stage III melanoma or aggressive appearing S-UBS with significant lymph node involvement were included. RESULTS: We found two major causes of diagnosis delay: patients with amelanotic lesions misdiagnosed as having a wart and cases reviewed by non-expert pathologists upfront. The side effects from interferon therapy requiring dose adjustments included neutropenia, thrombocytopenia and mood disturbances. There was wide variability in surveillance scan utilization, therefore leading to variability in patient radiation exposure. Unlike melanoma patients, none of the S-UBS patients experienced disease progression or death. CONCLUSIONS: This study highlights the challenges with the initial clinical diagnosis and pathological sub-categorization of the pediatric S-UBS/melanoma spectrum of skin lesions and emphasizes the role of expert pathology review upfront. Further, education at the primary care level could improve accurate and timely diagnoses. Earlier diagnosis could spare patients from more extensive interventions, metastatic spread or adverse outcomes in this patient population. This study is limited due to its retrospective, single-institution perspective.
BACKGROUND: The diagnosis and management of pediatric melanomas is challenging given the presence of both melanomas and histologically aggressive Spitz tumors of undetermined biological significance (S-UBS) in this age group. Study objectives were to examine: factors leading to diagnostic delays, therapy side effects and patient outcomes in these diagnostic groups. METHODS: A retrospective case review was performed using The University of Michigan's pediatric oncology database over a 13-year timespan. Patients referred to our clinic for consideration of interferon therapy due to a diagnosis of a stage III melanoma or aggressive appearing S-UBS with significant lymph node involvement were included. RESULTS: We found two major causes of diagnosis delay: patients with amelanotic lesions misdiagnosed as having a wart and cases reviewed by non-expert pathologists upfront. The side effects from interferon therapy requiring dose adjustments included neutropenia, thrombocytopenia and mood disturbances. There was wide variability in surveillance scan utilization, therefore leading to variability in patient radiation exposure. Unlike melanoma patients, none of the S-UBS patients experienced disease progression or death. CONCLUSIONS: This study highlights the challenges with the initial clinical diagnosis and pathological sub-categorization of the pediatric S-UBS/melanoma spectrum of skin lesions and emphasizes the role of expert pathology review upfront. Further, education at the primary care level could improve accurate and timely diagnoses. Earlier diagnosis could spare patients from more extensive interventions, metastatic spread or adverse outcomes in this patient population. This study is limited due to its retrospective, single-institution perspective.
Authors: Fariba Navid; Wayne L Furman; Martin Fleming; Bhaskar N Rao; Sandra Kovach; Catherine A Billups; Alvida M Cain; Rex Amonette; Jesse J Jenkins; Alberto S Pappo Journal: Cancer Date: 2005-02-15 Impact factor: 6.860
Authors: Lorenzo Cerroni; Raymond Barnhill; David Elder; Geoffrey Gottlieb; Peter Heenan; Heinz Kutzner; Philip E LeBoit; Martin Mihm; Juan Rosai; Helmut Kerl Journal: Am J Surg Pathol Date: 2010-03 Impact factor: 6.394
Authors: Katherine J Ransohoff; Prajakta D Jaju; Prajaka D Jaju; Jean Y Tang; Michele Carbone; Sancy Leachman; Kavita Y Sarin Journal: J Am Acad Dermatol Date: 2016-03 Impact factor: 11.527
Authors: Rajni V Mandal; Rajmohan Murali; Kurt F Lundquist; Bruce D Ragsdale; Peter Heenan; Stanley W McCarthy; Martin C Mihm; Richard A Scolyer; Artur Zembowicz Journal: Am J Surg Pathol Date: 2009-12 Impact factor: 6.394
Authors: Mathew W Ludgate; Douglas R Fullen; Julia Lee; Lori Lowe; Carol Bradford; James Geiger; Jennifer Schwartz; Timothy M Johnson Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: Daniel A Anaya; Yan Xing; Lei Feng; Xuelin Huang; Luis H Camacho; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Janice N Cormier Journal: Cancer Date: 2008-05-01 Impact factor: 6.860